Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Ранг среди акций #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Цена акции
$0.01292666
Последняя синхронизация: 2025-04-08
Рыночная капитализация
$157.54K
Изменение (1 день)
6.84%
Изменение (1 год)
0.00%
Страна
GB
Торговля Synairgen plc (SNG)

Категория

Коэффициент P/S для Synairgen plc (SNG)
Коэффициент P/S на August 2026 TTM: 0.00
Согласно последним финансовым отчетам и цене акций Synairgen plc, текущий коэффициент P/S (TTM) составляет 0.00. В конце 2022 он составлял 0.00.
История P/S для Synairgen plc с 2004 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 86.19K 5,474.43%
2017 1.55K 0.00%
2016 0.00 -100.00%
2015 589.54K 12,229.42%
2014 4.78K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 68.65 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 134.85 -99.56%
2006 30.85K 158.87%
2005 11.92K 8,695.11%
2004 135.48 0.00%
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE